Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 139 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Epigenetic Disorder Clear all
Recruiting No phase listed Observational Accepts healthy volunteers

Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Lung Cancer

NCT07008664
View directory record Official record
Conditions
Lung Cancer, Lung Cancer Screening, Healthy Volunteers (HV), Unhealthy Volunteers
Interventions
Epigenetic Signature Assay
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2032
U.S. locations
1
States / cities
Glen Burnie, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 22, 2026, 5:10 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Epigenetics of TNBC in Overweight and Obese Hispanic & Non-Hispanic White Women

NCT04291950
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Needle core biopsy
Procedure
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Oct 22, 2026, 5:10 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Epigenetic Markers of B-Cell Function in Low Birth Weight Infants

NCT00925925
View directory record Official record
Conditions
Low Birth Weight, Small for Gestational Age, Immunodeficiency
Interventions
Cord blood collection for analysis
Other
Lead sponsor
University of Utah
Other
Eligibility
Up to 2 Hours
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Oct 22, 2026, 5:10 AM EDT
Recruiting No phase listed Observational

Molecular Epidemiology of Pediatric Germ Cell Tumors

NCT05564026
View directory record Official record
Conditions
Germ Cell Tumor, Germinoma, Teratoma, Embryonal Carcinoma, Yolk Sac Tumor, Choriocarcinoma, Mixed Germ Cell Tumor, Late Effects, Pediatric Germ Cell Tumor
Interventions
Questionnaire Administration, Tumor Specimen Collection, Germline DNA Samples, Blood Sample Collection
Other · Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
Not listed
Enrollment
1,151 participants
Timeline
2023 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 22, 2026, 5:10 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Exposure in Epigenetic Regulation of Immune Response in Chronic Beryllium Disease (CBD)

NCT02604693
View directory record Official record
Conditions
Chronic Beryllium Disease
Interventions
Nothing
Other
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 80 Years
Enrollment
148 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 29, 2021 · Synced Oct 22, 2026, 5:10 AM EDT
Active, not recruiting Phase 1 Interventional

Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL

NCT03240211
View directory record Official record
Conditions
PTCL, CTCL
Interventions
Pembrolizumab, Pralatrexate, Decitabine
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 90 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 22, 2026, 5:10 AM EDT
Recruiting Phase 1 Interventional

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

NCT06784193
View directory record Official record
Conditions
Advanced or Metastatic ER+ HER2- Breast Cancer (mBC), Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC), Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Breast Cancer, Fulvestrant, Palazestrant
Interventions
OP-3136, Fulvestrant, Palazestrant
Drug
Lead sponsor
Olema Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
13
States / cities
Gilbert, Arizona • Aurora, Colorado • Sarasota, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 22, 2026, 5:10 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Exogenous and Endogenous Risk Factors for Early-onset Colorectal Cancer

NCT05732623
View directory record Official record
Conditions
Colorectal Cancer, Early Onset Colorectal Cancer, Diet Habit, Risk Reduction
Interventions
Semi Quantitative Food Frequency Questionnaire (SQFFQ)
Behavioral
Lead sponsor
San Raffaele University
Other
Eligibility
18 Years to 49 Years
Enrollment
2,300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2035
U.S. locations
2
States / cities
Denver, Colorado • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 22, 2026, 5:10 AM EDT
Completed Phase 1 Interventional

A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer

NCT02512172
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Oral CC-486, Romidepsin, MK-3475
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 22, 2026, 5:10 AM EDT
Active, not recruiting Phase 2 Interventional

Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia

NCT01627041
View directory record Official record
Conditions
Acute Myeloid Leukemia, Adult Acute Basophilic Leukemia, Adult Acute Monoblastic Leukemia, Adult Acute Monocytic Leukemia, Adult Acute Myeloid Leukemia With Maturation, Adult Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-KMT2A, Adult Acute Myeloid Leukemia Without Maturation, Adult Acute Myelomonocytic Leukemia, Alkylating Agent-Related Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
Interventions
Cytarabine, Daunorubicin Hydrochloride, Decitabine, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 65 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
9
States / cities
Brewer, Maine • Buffalo, New York • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 22, 2026, 5:10 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Investigating Phenotypic, Epigenetic, and NeuroGenetic Traits in Rare and Ultra-rare Neurodevelopmental Disorders (Project PENGUIN)

NCT07329257
View directory record Official record
Conditions
Baker Gordon Syndrome, Rare Neurodevelopmental Conditions, Rare Neurogenetic Conditions, Syt-1 Disorder, Epilepsy, Seizure, Genetic Mutations, Autism in Children, Developmental Delay (Disorder)
Interventions
No Intervention: Observational Cohort
Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
Up to 99 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 22, 2026, 5:10 AM EDT
Terminated Phase 2 Interventional

Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

NCT00666497
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Interventions
Azacitidine, MGCD0103
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
60 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2015 · Synced Oct 22, 2026, 5:10 AM EDT
Terminated Phase 2 Interventional Results available

Azacitidine and Entinostat in Treating Patients With Stage I Non-Small Cell Lung Cancer That Has Been Removed By Surgery

NCT01207726
View directory record Official record
Conditions
Stage IA Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma
Interventions
Azacitidine, Entinostat, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
9
States / cities
Los Angeles, California • Tampa, Florida • Annapolis, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2019 · Synced Oct 22, 2026, 5:10 AM EDT
Completed Phase 2 Interventional Results available

Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With NSCLC: PRECISE Trial

NCT02664181
View directory record Official record
Conditions
Lung Cancer, Non-small Cell Lung Cancer
Interventions
Nivolumab, oral decitabine, Tetrahydrouridine
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
2
States / cities
Bethesda, Maryland • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Oct 22, 2026, 5:10 AM EDT
Recruiting Phase 2 Interventional

Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker

NCT07060001
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Acute Myeloid Leukaemia (AML)
Interventions
5hmC Biomarker, Venetoclax, Decitabine 20 mg/m²/day for 5 days, Azacitidine (AZA), Cytarabine (Ara-C), Anthracycline
Diagnostic Test · Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 22, 2026, 5:10 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Periodontal Inflammation and Epigenetics in Obese Individuals

NCT07610902
View directory record Official record
Conditions
Obesity, Periodontitis
Interventions
Non-surgical periodontal therapy will be administered
Procedure
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 22, 2026, 5:10 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Perinatal Autism Genetics and Epigenetics Study

NCT07738003
View directory record Official record
Conditions
Autism Disorders and Maternal Stress, Development Delay, Prenatal Stress, Social Behavior
Interventions
Change in child's DNA methylation, Perinatal stress, Early social experience, Polygenic risk scores for social communication and repetitive behavior
Genetic · Behavioral
Lead sponsor
University of Iowa
Other
Eligibility
0 Years to 50 Years
Enrollment
7,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 22, 2026, 5:10 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Salivary miRNA Diagnostic Test for Autism

NCT02832557
View directory record Official record
Conditions
Autism Spectrum Disorder, Developmental Delay
Interventions
Salivary collection, Vineland Adaptive Behavior Scale-III Assessment, Medical history questionaire, Autism Diagnostic Observation Schedule -2nd edition (ADOS-2), Mullen Scales of Early Learning
Other
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
24 Months to 48 Months
Enrollment
998 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Oct 22, 2026, 5:10 AM EDT
Completed Phase 4 Interventional Results available

Paliperidone and Lithium in the Treatment of Suicidality - Treatment Indication and Epigenetic Regulation

NCT01134731
View directory record Official record
Conditions
Major Depressive Disorder, Suicidal Ideation
Interventions
paliperidone, lithium, Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 3, 2016 · Synced Oct 22, 2026, 5:10 AM EDT
Recruiting No phase listed Observational

Development of a cfDNA 5mC/5hmC-based Biomarker Panel to Predict Targeted Therapy Efficacy in mCRC

NCT07224841
View directory record Official record
Conditions
CRC (Colorectal Cancer)
Interventions
cfDNA 5mC/5hmC Sequencing (EpiDRIVE Discovery Phase), EpiDRIVE Assay (Targeted Sequencing / qPCR Validation)
Diagnostic Test
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 22, 2026, 5:10 AM EDT
Not listed No phase listed Observational

Epigenetic Regulation of Altered T-cell Immunity in Sarcoidosis

NCT03145922
View directory record Official record
Conditions
Sarcoidosis, Sarcoidosis, Pulmonary
Interventions
Observational Study
Other
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 85 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Oct 22, 2026, 5:10 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Re-expression of ER in Triple Negative Breast Cancers

NCT01194908
View directory record Official record
Conditions
Breast Cancer, Breast Tumors, Breast Neoplasms
Interventions
Decitabine, LBH589, Tamoxifen
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 26, 2015 · Synced Oct 22, 2026, 5:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Salivary Biomarkers for Concussion Recovery

NCT05379920
View directory record Official record
Conditions
Concussion, Brain
Interventions
High Volume Aerobic Exercise, Low Volume Aerobic Exercise
Behavioral
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
13 Years to 18 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 3, 2024 · Synced Oct 22, 2026, 5:10 AM EDT
Completed No phase listed Observational

Psychological, Psychophysical and Epigenetic Determinants of Chronic Pain After Cytoreductive - Hyperthermic Intraoperative Chemotherapy

NCT05083338
View directory record Official record
Conditions
Appendix Carcinoma, Carcinomatosis, Colorectal Carcinoma, Gastric Carcinoma, Malignant Peritoneal Neoplasm, Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Pain Assessment, Questionnaire Administration
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 13, 2024 · Synced Oct 22, 2026, 5:10 AM EDT